Ünlü Gülhan, Yıldız Halime Tozak, Yıldız Osman Mert
Faculty of Medicine, Department of Medical Pharmacology, Kirsehir Ahi Evran University, Kirsehir, Türkiye.
Faculty of Medicine, Department of Histology and Embryology, Kirsehir Ahi Evran University, Kirsehir, Türkiye.
BMC Nephrol. 2025 Jul 1;26(1):295. doi: 10.1186/s12882-025-04245-6.
Myocardial infarction is a major cause of morbidity and mortality, often leading to heart and kidney dysfunction. Despite advancements in treatment, the link between heart and kidney damage is poorly understood. This study aims to evaluate the potential protective effect of Carvacrol, a natural bioactive compound, on kidney injury induced by myocardial infarction.
In this experimental study, 32 male Wistar rats were divided into four groups: Control, Carvacrol (50 mg/kg), Myocardial Infarction (85 mg/kg isoproterenol), and Myocardial Infarction + Carvacrol (50 mg/kg Carvacrol + 85 mg/kg isoproterenol). Carvacrol was administered for six weeks, and myocardial infarction was induced with isoproterenol. Blood pressure, biochemical parametres (creatinin kinase, lactate dehydrogenase, urea, creatinine, GDF-15, IL-6), and kidney tissue histopathology were evaluated.
Biochemical analysis showed increased Creatinin Kinase and Lactate Dehydrogenase levels in the Myocardial Infarction group compared to controls(p = 0.023, p = 0.020), with carvacrol reducing these markers. IL-6 and GDF-15 levels were elevated in both the Myocardial Infarction and Myocardial Infarction + Carvacrol groups (p = 0.009, p < 0.001). Blood pressure was significantly reduced in the Myocardial Infarction group. Histopathological examination revealed severe kidney damage in the Myocardial Infarction group, while Carvacrol treatment showed less kidney damage, with only mild tubular dilation and rare necrosis.
Carvacrol appears to have protective effects against kidney injury in myocardial infarction. It reduced myocardial injury markers and kidney damage, suggesting its potential therapeutic use in cardiorenal syndrome. Further studies are needed to understand its mechanisms and clinical applications in cardiovascular and renal diseases.
心肌梗死是发病和死亡的主要原因，常导致心脏和肾脏功能障碍。尽管治疗取得了进展，但心脏和肾脏损伤之间的联系仍知之甚少。本研究旨在评估天然生物活性化合物香芹酚对心肌梗死诱导的肾损伤的潜在保护作用。
在本实验研究中，32只雄性Wistar大鼠被分为四组：对照组、香芹酚组（50毫克/千克）、心肌梗死组（85毫克/千克异丙肾上腺素）和心肌梗死+香芹酚组（50毫克/千克香芹酚+85毫克/千克异丙肾上腺素）。香芹酚给药六周，用异丙肾上腺素诱导心肌梗死。评估血压、生化参数（肌酸激酶、乳酸脱氢酶、尿素、肌酐、生长分化因子15、白细胞介素-6）和肾脏组织病理学。
生化分析显示，与对照组相比，心肌梗死组的肌酸激酶和乳酸脱氢酶水平升高（p = 0.023，p = 0.020），香芹酚降低了这些标志物。心肌梗死组和心肌梗死+香芹酚组的白细胞介素-6和生长分化因子15水平均升高（p = 0.009，p < 0.001）。心肌梗死组血压显著降低。组织病理学检查显示心肌梗死组肾脏损伤严重，而香芹酚治疗显示肾脏损伤较轻，仅轻度肾小管扩张和罕见坏死。
香芹酚似乎对心肌梗死中的肾损伤具有保护作用。它降低了心肌损伤标志物和肾脏损伤，表明其在心肾综合征中的潜在治疗用途。需要进一步研究以了解其在心血管和肾脏疾病中的作用机制和临床应用。
